Posts by Mark Bryant
Clyde Publishes Excitation-Coupling Data

Clyde Biosciences is the leading in vitro cardiomyocyte safety provider with a track record in developing fully validated safety assays to help solve industry wide challenges regarding cardiovascular liabilities beyond that of hERG. Working with the FDA and large pharmas, Clyde has been instrumental in developing next generation assays for pro arrhythmic risk (CiPA Assay) and negative inotropy (CRACKIT). This publication in the Journal of Cardiovascular Pharmacology highlights our excitation-coupling assay for the parallel assessment of voltage and contractility effects using hiPSC cardiomyocytes.

Read More
Mark Bryant
Clyde Founders contribute to FDA/HESI CiPA publication

It has been long established that a hERG assay is not a sufficient predictor for pro-arrythmic actions of a drug (Gintant, 2011; Lu et al., 2008). Since 2013, the FDA has led an initiative designed to validate the use of hiPSC cardiomyocytes in an assay to improve prediction of drug-induced pro-arrhythmic risk (Comprehensive invitro Pro-arrythmia Assay – CiPA). This initiative has stimulated the use if iPSC-cardiomyocytes in industrial work and a growing number of regulatory filings now contain data from iPSC cardiomyocytes.

Read More
Mark Bryant